Rapid Micro Biosystems reported Q2 2026 revenue of $8.05 million, an 11% increase year-over-year, driven by strong product and consumable sales. The company placed its 200th Growth Direct system, boosting recurring revenue to 63% of total revenue. However, EPS was -$0.27, missing analyst expectations for the fourth consecutive quarter. This shows solid top-line growth but ongoing challenges in profitability.
A Vice President at WM sold 1,365 shares valued at $300,000. Insider sales like this can indicate the executive's personal financial decisions but do not necessarily reflect the company's outlook. Investors should watch for any further insider activi...
YETI has raised its fiscal year 2026 guidance, now expecting 10-12% growth in adjusted operating income, 14.9% operating margins, and pro forma EPS of $2.94-$3.00. The company benefits from accelerating direct-to-consumer sales, strong 19% year-over-...
Bitcoin Cash surged 28.76% to $341.18, leading the day's top gainers amid renewed interest driven by discussions of potential network upgrades. This rise highlights investor focus on scalable alternatives to Bitcoin, as Bitcoin Cash offers larger blo...
Useless Coin (USELESS) has surged significantly in the past 24 hours, outperforming the broader crypto market which rose 4.2% to a $2.91 trillion market cap. This rally is driven by Bitcoin's breakout and a rotation of capital into memecoins like PEP...
Hedera's HBAR token has surged nearly 29% from its recent low, reaching about $0.097 and surpassing a long-standing resistance near $0.086. The rally shows stronger buyer interest with increased trading volume and the price now above its 200-day aver...
